ERIS Lifesciences Ltd

NSE : ERIS

BSE: 540596

SECTOR : PHARMACEUTICALS

No data to show from BSE

52w high/low	₹863 / ₹473.5
P/E ratio	33.07
Dividend	0.87
ROE	16.96
ROCE	15.66
Face value	1
Book value	₹180.24Cr
Market capital	₹11,509.62Cr

Shareholding pattern

What is shareholding pattern? Who are shareholders?

Shareholding pattern represents the percentage of share ownership that different investors are holding in the company. A company can have multiple investors who invest in its shares. These are called as shareholders and there are two major categories of shareholders - promoters and public shareholders.

Promoters are typically the founders and public shareholders could be financial institutes like banks, insurance companies, domestic institutional investors, foreign institutional investors and common public.

Cash flow

What is a cash flow statement?

It is a financial statement that offers aggregate statistics on all cash inflows a business collects from its continuing activities and external sources of investment. It also includes all cash outflows over a specified time paying for company operations and investments.The main components of the CFS are cash from three areas: operating, investing, and financing activities...Read more

Balance Sheet

What is a balance sheet?

A balance sheet is a financial statement that records the assets, liabilities, and equity of a company at a certain point in time and provides a basis for estimating return rates and determining the capital structure. It offers a snapshot of what an entity owns and owes, as well as the sum that shareholders spend.The balance sheet complies with the following accounting equation in which assets on the one side, and liabilities plus shareholders' equity on the other, balance out:

Assets = Liabilities + Shareholder's Equity

This is used to conduct fundamental analysis or the estimation of financial ratios alongside other essential financial statements, such as income statement and statement of cash flows...Read more

Profit and loss

What is a profit and loss statement?

A profit and loss statement is a financial statement that represents the revenues, costs and expenses that the company has incurred during a quater or a fiscal year. It is also sometimes referred to as statement of profit and loss, income statement or statement of operations. This statement basically shows the investors and management whether the company has incurred profits or losses and in which areas.

Key Ratios

PE TTM

33.07

P/B

4.69

ROE

16.96

ROCE

15.66

Dividend yield

0.87%

EPS TTM

25.58

EBTIDA Growth

1.85

D/E

0.24

Sector PE

45.33

₹180.24Cr

Peer Comparison

Dividends

What are dividends?

Dividend, in financial terms, means a certain amount shared with shareholders of a company or a mutual fund on a regular basis – monthly, quarterly or annually. Read more

Bonuses

What are bonuses?

A bonus issue is an offer given to the existing shareholders of the company to subscribe for additional shares. Instead of increasing the dividend payout, the companies off... Read more

Company News

Sorry, we do not have any data here.

Sector News

Sorry, we do not have any data here.

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the company was converted into a public limited company and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. As on 31 March 2019, the Company has 5 subsidiaries, of which 4 are wholly owned subsidiaries. In 2007, the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008, the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment.